Current filters:

Lu AE58054

Promising results with Lu AE58054 as add-on to donepezil, in cognitive symptoms of Alzheimer's disease


Danish CNS specialist Lundbeck (LUN: CO) and Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) presented…

donepezilLu AE58054LundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck could get $825 million in further deal with Otsuka, for Alzheimer's drug condidate


Danish CNS specialist Lundbeck (LUN: CO) has entered a license and development agreement for its Lu AE58054,…

GlobalLicensingLu AE58054LundbeckNeurologicalOtsukaPharmaceutical

New products helping overcome generic competition for Lexapro, says Lundbeck


Danish CNS drugmaker Lundbeck reported first-half 2012 sales of 7.34 billion Danish kroner ($1.22 billion),…

FinancialLicensingLu AE58054LundbeckPharmaceutical

Alzheimer's drug candidate Lu AE58054 meets primary endpoint, says Lundbeck


Danish CNS drug specialist Lundbeck (LUND: DC) announced this morning that its investigational compound…

Lu AE58054LundbeckNeurologicalPharmaceuticalResearch

Back to top